View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Sanofi: Information concerning the total number of voting rights and s...

Sanofi: Information concerning the total number of voting rights and shares - April 2025 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,452,461,656Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry und...

 PRESS RELEASE

Sanofi: Informations relatives au nombre de droits de vote et d'action...

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Avril 2025 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers SanofiSociété anonyme au capital de 2 452 461 656 euros Siège social : 46, avenue de la Grande Armée - 75017 Paris395 030 844 R.C.S. Paris DateNombre d’actions composant le capital Nombre réel de droits de vote (déduction faite des actions auto-détenues)Nombre théorique de droits de vote (y compris actions a...

Luis Arredondo
  • Luis Arredondo

ACS: 1Q’25 RESULTS, CHANGE OF RECOMMENDATION TO UNDERWEIGHT AND T.P. U...

1Q'25 vs. 1Q'24 Results: Sales: € 11.790 Bn (+35.4% vs. +33.6% BS(e) and +25.1% consensus); EBITDA: € 699.0 M (+51.6% vs. +50.7% BS(e) and +47.7% consensus); EBIT: € 470.0 M (+43.7% vs. +28.4% BS(e) and +71.3% consensus); Net Profit: € 191.0 M (+7.9% vs. +6.5% BS(e) and -3.4% consensus);

Luis Arredondo
  • Luis Arredondo

ACS: RDOS. 1T’25, CAMBIO DE RECOMENDACIÓN A INFRAPONDERAR Y DE P.O. AL...

Rdos. 1T'25 vs 1T'24: Ventas: 11.790 M euros (+35,4% vs +33,6% BS(e) y +25,1% consenso); EBITDA: 699,0 M euros (+51,6% vs +50,7% BS(e) y +47,7% consenso); EBIT: 470,0 M euros (+43,7% vs +28,4% BS(e) y +71,3% consenso); BDI: 191,0 M euros (+7,9% vs +6,5% BS(e) y -3,4% consenso);

Research Department
  • Research Department

IBERIAN DAILY 13 MAY + 1Q’25 RESULTS. HIGHLIGHTS AND REST OF PREVIEWS ...

NEWS SUMMARY: ACCIONA, ACCIONA ENERGÍA, ACS, ELECTRICITY AND GAS SECTOR, GRIFOLS. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 1Q’25 results to be released over the coming days in Spain. Markets become euphoric The agreement between the US and China to lower tariffs fuelled global stock markets again. In the STOXX 600, most sectors (14/20) ended the week with gains, led by ...

Research Department
  • Research Department

INFORME DIARIO 13 MAYO + RDOS. ESPAÑA Y EUROPA 1T’25. IDEAS DESTACADAS...

COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: ACS, GRIFOLS, ACCIONA, ACCIONA ENERGÍA, SECTOR ELÉCTRICO Y GASISTA. EUROPA: BAYER, MUNICH RE. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 1T’25 que se publicarán en España y Europa en los próximos días. El mercado se pone en modo eufórico El acuerdo entre EE.UU. y China para reducir los aranceles impuls...

Luis Arredondo
  • Luis Arredondo

ACS: RDOS. 1T’25 DE HOCHTIEF, EN LÍNEA EN OPERATIVO. MANTIENE GUIDANCE...

Hochtief (~80% ACS) acaba de publicar unos Rdos. 1T’25 que estuvieron por encima en ventas (+32% vs 1T’24 vs +20% consenso; +25% LfL) y bastante en línea en BDI operativo (167 M euros vs 163 M euros consenso; +18% vs 1T’24).

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

MFN Drug Pricing - Impact and Implementation (Thematic, 5pgs)

Ahead of today’s signing of an Executive Order to introduce a Most Favoured Nation approach to drug pricing in the US, we show that net pricing in the EU is c.50% lower than in the US & which companies have most to lose from MFN. We also show that, in reality,

Anthony Dick ... (+2)
  • Anthony Dick
  • Michael Foundoukidis
Ignacio Romero
  • Ignacio Romero

CIE AUTOMOTIVE: VEMOS VALOR EN MEDIO DE LA TORMENTA (ANÁLISIS BANCO SA...

Vemos valor en medio de la tormenta. SOBREPONDERAR. La acción ha sufrido un derating en valoración por las dudas acerca del crecimiento de la industria del automóvil. Así, cotiza a EV/EBITDA’25e de 6x y PER’25e de 9x vs media histórica de 8x y 13x respectivamente. Creemos que CIE debería salir mejor parada de lo que podría estar descontando el mercado y, aunque rebajamos el P.O. un -12% hasta 29,61 euros/acc. (potencial +27%), reiteramos nuestra recomendación de SOBREPONDERAR porque consideramos...

Research Department
  • Research Department

INFORME DIARIO 05 MAYO + RDOS. ESPAÑA Y EUROPA 1T’25. IDEAS DESTACADAS...

COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: CIE AUTOMOTIVE, GREENING. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 1T’25 que se publicarán en España y Europa en los próximos días. El empleo americano les da impulso a las bolsas Semana de avances en las bolsas a ambos lados del Atlántico ante la relajación del riesgo arancelario y una campaña de re...

Research Department
  • Research Department

IBERIAN DAILY 05 MAY + 1Q’25 RESULTS. HIGHLIGHTS AND REST OF PREVIEWS ...

NEWS SUMMARY: CIE AUTOMOTIVE, GREENING. At the end of today’s report, and during the entire results season, we will include a presentation with positive and negative results highlights and previews for the 1Q’25 results to be released over the coming days in Spain. US employment data spurs markets It was a week of gains on both sides of the Atlantic in view of the waning tariff risk and a results season that has acted as a support. On the macro side, in the euro zone April’s preliminary gener...

 PRESS RELEASE

Sanofi: Information concerning the total number of voting rights and s...

Sanofi: Information concerning the total number of voting rights and shares - March 2025 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,452,461,656Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry und...

 PRESS RELEASE

Sanofi: Informations relatives au nombre de droits de vote et d'action...

Sanofi: Informations relatives au nombre de droits de vote et d'actions – Mars 2025 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers SanofiSociété anonyme au capital de 2 452 461 656 euros Siège social : 46, avenue de la Grande Armée - 75017 Paris395 030 844 R.C.S. Paris DateNombre d’actions composant le capital Nombre réel de droits de vote (déduction faite des actions auto-détenues)Nombre théorique de droits de vote (y compris actions a...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch